OUYOUBI
Neratinib Maleate Tablets
Approved for the extended adjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer, following adjuvant trastuzumab-based therapy
Approved in China in September 2023 as the first domestic generic of neratinib maleate tablets
Recognized in two leading national guidelines — the 2025 CSCO Breast Cancer Guidelines and the 2025 Essential Edition of the Breast Cancer Diagnosis and Treatment Guidelines by the China Anti-Cancer Association and Chinese Society of Oncology — as the only recommended adjuvant intensification therapy for HER2+ breast cancer patients following H(P) treatment
OUNALIN
Eribulin Mesylate Injection
Approved for the treatment of locally advanced or metastatic breast cancer in patients previously treated with at least two chemotherapy regimens, including an anthracycline and a taxane
Successfully introduced in March 2025, indicated for locally advanced or metastatic breast cancer, with launch progress among the top tier of domestic generics
Supported by multiple international and domestic multicenter pivotal trials showing that eribulin significantly improves overall survival (OS), progression-free survival (PFS), and objective response rate (ORR) in patients previously treated with anthracyclines and taxanes; Recommended by two leading national guidelines — the 2025 CSCO Breast Cancer Guidelines and the 2025 Essential Edition of Breast Cancer Diagnosis and Treatment Guidelines by the China Anti-Cancer Association and Chinese Society of Oncology — as a chemotherapy option for advanced breast cancer